Prime Medicine
Aaron Chang has a diverse work experience in the field of computational biology and bioinformatics. Aaron is currently serving as the VP of Computational Sciences at Prime Medicine since October 2020. Prior to this, they worked at Fulcrum Therapeutics as an Executive Director of Computational Biology from January 2019 to October 2020, and as a Senior Director of Computational Biology from October 2016 to December 2018.
Before joining Fulcrum Therapeutics, Aaron held the position of Executive Director of the Center for Computational Biology & Bioinformatics at the University of California, San Diego - School of Medicine from 2014 to 2016. Aaron also worked at the Baylor Institute for Immunology Research, where they held the role of Associate Investigator and Adjunct Assistant Professor from 2012 to 2014.
Prior to that, Aaron served as an Associate Director of Computational Biology at Regulus Therapeutics from 2008 to 2011, and as a Senior Research Scientist in Informatics at Merck & Co - Rosetta Inpharmatics from 2005 to 2008. Aaron started their career as a Fellow in Biomedical & Health Informatics at the University of Washington - School of Medicine from 2002 to 2005.
Aaron Chang has a Ph.D. from the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences. Prior to this, they earned an S.B. degree from the Massachusetts Institute of Technology.
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.